INDIAN PHARMACOPOEIA COMMISSION



National Coordination Centre- Pharmacovigilance Programme of India (PvPI) MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120- 2783392, 2783400, 2783401, Fax: 0120-2783311 e-mail: pvpi.ipc@gov.in, ipclab@vsnl.net, Web: www.ipc.gov.in

File No. IPC/NCC-PvPI/DSA/2016-17/07

November 2016

Drug Safety Alerts

The preliminary analysis of SUSARs from the PvPI database reveals that the following drugs are associated with the risks as given below.

Table

Sl.No	Suspected Drugs	Indication	Adverse Reactions
1	Cabergoline	For the treatment of hyperprolactinemia and inhibition of lactation	Steven Johnson Syndrome
2	Amlodipine	Angina, hypertension, Coronary artery disease	Alopecia
3	Nitrofurantoin	Urinary tract infections; cystitis	Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)
4	Cefoperazone Sulbactam	For treatment of RTI, UTI (lower & upper), Septicemia, Meningitis, Skin & Soft tissue infection, Endometritis, Other infection of genital tract, Intra abdominal infection bone & joint infection	Acute Generalised Exanthematous Pustulosis (AGEP)

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse events while prescribing/consuming above suspected drugs and report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/ Medicines Side Effect Reporting Form for Consumer (http://www.ipc.gov.in) or by PvPI Helpline No. 1800-180-3024.